Sage Capital Advisors’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-10,400
Closed -$111K 143
2024
Q3
$111K Hold
10,400
0.03% 138
2024
Q2
$103K Buy
+10,400
New +$107K 0.03% 133
2023
Q1
Sell
-10,800
Closed -$132K 133
2022
Q4
$132K Hold
10,800
0.06% 126
2022
Q3
$113K Sell
10,800
-600
-5% -$6.68K 0.06% 116
2022
Q2
$122K Sell
11,400
-450
-4% -$3.71K 0.06% 102
2022
Q1
$103K Buy
+11,850
New +$111K 0.04% 105
2021
Q4
Sell
-10,850
Closed -$104K 109
2021
Q3
$104K Buy
+10,850
New +$111K 0.04% 104
2020
Q1
Sell
-10,200
Closed -$99K 106
2019
Q4
$99K Buy
+10,200
New +$93.4K 0.06% 97
2019
Q3
Sell
-10,200
Closed -$135K 101
2019
Q2
$135K Sell
10,200
-2,000
-16% -$25.4K 0.09% 89
2019
Q1
$166K Sell
12,200
-200
-2% -$2.44K 0.11% 87
2018
Q4
$119K Buy
12,400
+1,500
+14% +$16.5K 0.09% 81
2018
Q3
$132K Buy
10,900
+700
+7% +$9.79K 0.08% 85
2018
Q2
$159K Sell
10,200
-500
-5% -$7.56K 0.11% 84
2018
Q1
$161K Sell
10,700
-500
-4% -$7.61K 0.11% 82
2017
Q4
$161K Buy
11,200
+1,000
+10% +$13.7K 0.1% 81
2017
Q3
$154K Buy
+10,200
New +$135K 0.11% 81

Other funds holding FOLD

Sage Capital Advisors's FOLD Position: Q4 2024 in Review

Sage Capital Advisors sold out of Amicus Therapeutics (FOLD) in Q4 2024, closing a stake of 10,400 shares — an estimated $111K sold.

Sage Capital Advisors first reported a position in FOLD in Q3 2017 and held it in 16 quarters. The position peaked at $166K in Q1 2019. 290 funds tracked by Wall St. Rank hold FOLD as of Q4 2024.

  • Sage Capital Advisors reported no remaining Amicus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Sage Capital Advisors sold 10,400 Amicus Therapeutics shares in Q4 2024, an estimated $111K.
  • Sage Capital Advisors first reported a position in Amicus Therapeutics in Q3 2017 and held it in 16 quarters.
  • Sage Capital Advisors's Amicus Therapeutics position peaked at $166K in Q1 2019.
  • 290 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2024.

Based on Sage Capital Advisors's 13F filing for Q4 2024, filed 10 Jan 2025.